ANDRES MANUEL R
CERVANTES RUIPEREZ
CATEDRÁTICO/A DE UNIVERSIDAD
Instituto de Salud Carlos III
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Salud Carlos III (40)
2024
2023
-
European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer
Cancer Treatment Reviews, Vol. 115
-
In the Literature: January 2023
ESMO Open
-
In the Literature: March 2023
ESMO Open
-
Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
Annals of Oncology, Vol. 34, Núm. 1, pp. 10-32
2022
-
Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences
Clinical Cancer Research, Vol. 28, Núm. 3, pp. 507-517
-
Clinical management of metastatic colorectal cancer in the era of precision medicine
CA Cancer Journal for Clinicians, Vol. 72, Núm. 4, pp. 372-401
-
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma
Cancer Immunology, Immunotherapy, Vol. 71, Núm. 2, pp. 417-431
-
In the literature: April 2022
ESMO Open
-
In the literature: December 2021
ESMO Open
-
In the literature: February 2022
ESMO Open
-
Paclitaxel Induces Epidermal Molecular Changes and Produces Subclinical Alterations in the Skin of Gynecological Cancer Patients
Cancers, Vol. 14, Núm. 5
2021
-
Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy
Annals of Oncology, Vol. 32, Núm. 5, pp. 590-599
-
First-In-Human Phase I Study of a Next-Generation, Oral, TGFb Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer
Clinical Cancer Research, Vol. 27, Núm. 24, pp. 6666-6676
-
In the literature: August 2021
ESMO Open
-
In the literature: December 2020
ESMO Open
-
In the literature: October 2021
ESMO Open
-
Molecular profiling of advanced solid tumours. The impact of experimental molecular-matched therapies on cancer patient outcomes in early-phase trials: the MAST study
British Journal of Cancer, Vol. 125, Núm. 9, pp. 1261-1269
-
Radiomics and radiogenomics in head and neck squamous cell carcinoma: Potential contribution to patient management and challenges
Cancer Treatment Reviews, Vol. 99
-
Reply to the letter to the editor: adjuvant nivolumab for the management of the pathological residual disease in esophageal or junctional tumors: a word of caution by P.K. Garg, R. Kumar and P. Dixit
Annals of Oncology